Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort.

J Clin Mov Disord 2014 26;1. Epub 2014 Nov 26.

Departments of Neurology, Neurosurgery and Psychiatry, McKnight Brain Institute, University of Florida, 100 S Newell Dr Rm-L3-101, Gainesville, 32611 FL USA.

Background: To determine if testosterone levels are influenced by dopaminergic therapy in Parkinson disease (PD) patients. Testosterone level has been reported to be low in patients with PD and other neurodegenerative diseases. In this study, we sought to determine whether dopaminergic therapy (i.e. levodopa and dopamine agonist) influenced testosterone levels. We used a cohort of consecutive male patients from the INSPECT trial--a multi-center, prospective, study that primarily investigated the effects of short-term treatment with pramipexole or levodopa on [(123)I] B-CIT SPECT imaging in early PD.

Methods: Testosterone levels were drawn on consenting male subjects with early PD who enrolled in the INSPECT trial at three study visits (baseline, 12 weeks post-treatment, and 8-12 weeks post-washout). Subjects were randomized to: no treatment, pramipexole (up to 3 mg) or levodopa (up to 600 mg). Testosterone levels were obtained twice (prior to 10 AM) and averaged for each of three study visits.

Results: Thirty two male patients participated in this sub-study and there were no significant differences in disease characteristics in the 3 groups at baseline. Twenty-nine patients completed the follow-up visits and were suitable for analysis. There were statistically significant differences in the change in free testosterone level, increased in both the levodopa group and pramipexole group but decreased in the untreated group at 12-weeks post-treatment. There were no significant differences in the changes of UPDRS total or motor scores, although there was a strong trend toward improvement in motor scores. The testosterone level persisted in its increase only in the pramipexole group at the end of the washout period.

Conclusion: These preliminary data support the premise that dopaminergic medications do not reduce testosterone levels in early PD patients.

Download full-text PDF

Source
http://dx.doi.org/10.1186/2054-7072-1-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711001PMC
January 2016
523 Reads

Publication Analysis

Top Keywords

testosterone levels
20
testosterone level
16
testosterone
9
treatment pramipexole
8
dopaminergic therapy
8
male patients
8
motor scores
8
parkinson disease
8
three study
8
pramipexole group
8
patients
6
levodopa
5
levels
5
8-12 weeks
4
trend improvement
4
post-treatment 8-12
4
imaging early
4
weeks post-washout
4
improvement motor
4
subjects randomized
4

References

(Supplied by CrossRef)

KL Chou et al.
Mov Disord 2007

MS Okun et al.
J Neurol Neurosurg Psychiatry 2004

MS Okun et al.
Neurology 2004

MS Okun et al.
Arch Neurol 2006

MS Okun et al.
Arch Neurol 2002

MS Okun et al.
Arch Neurol 2002

E Mitchell et al.
J Clin Neurosci 2006

AJ Hughes et al.
J Neurol Neurosurg Psychiatry 1992

ME Molitch et al.
Pituitary 2005

I Shimon et al.
Eur J Endocrinol 2007

Similar Publications